• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

纤溶酶原激活物抑制剂-1转基因小鼠中反应位点依赖性的表型改变

Reactive site-dependent phenotypic alterations in plasminogen activator inhibitor-1 transgenic mice.

作者信息

Eren M, Gleaves L A, Atkinson J B, King L E, Declerck P J, Vaughan D E

机构信息

Division of Cardiovascular Medicine, Department of Medicine and Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.

出版信息

J Thromb Haemost. 2007 Jul;5(7):1500-8. doi: 10.1111/j.1538-7836.2007.02587.x. Epub 2007 Apr 16.

DOI:10.1111/j.1538-7836.2007.02587.x
PMID:17439629
Abstract

BACKGROUND

Plasminogen activator inhibitor-1 (PAI-1) is the major physiological inhibitor of plasminogen activators (PAs) and plays a role in the regulation of a number of physiological processes including the degradation of extracellular matrix proteins, cell proliferation and migration, and intracellular signaling.

AIM

To characterize the effects of durable expression of a stable form of human PAI-1 and to characterize important structure-function relationships in PAI-1 in vivo.

METHODS

We developed transgenic mice lines overexpressing stable variants of human PAI-1 under the control of the murine preproendothelin-1 promoter and characterized the phenotypic alterations displayed by transgenic mice.

RESULTS

Transgenic mice expressing an active form of human PAI-1 (PAI-1-stab) display complex phenotypic abnormalities including alopecia and hepatosplenomegaly. Reactive site mutant transgenic mice expressing inactive PAI-1 exhibit complete phenotypic rescue, while transgenic mice expressing PAI-1 with reduced affinity for vitronectin manifest all of the phenotypic abnormalities present in PAI-1-stab transgenic mice.

CONCLUSIONS

The protease inhibitory activity of PAI-1 toward PAs and/or other serine proteases is necessary and sufficient to promote complex phenotypic abnormalities and mediates many of the physiological effects of PAI-1 in vivo.

摘要

背景

纤溶酶原激活物抑制剂-1(PAI-1)是纤溶酶原激活物(PAs)的主要生理性抑制剂,在多种生理过程的调节中发挥作用,包括细胞外基质蛋白的降解、细胞增殖与迁移以及细胞内信号传导。

目的

表征稳定形式的人PAI-1的持久表达的影响,并在体内表征PAI-1中重要的结构-功能关系。

方法

我们构建了在小鼠前内皮素-1启动子控制下过表达人PAI-1稳定变体的转基因小鼠品系,并对转基因小鼠表现出的表型改变进行了表征。

结果

表达活性形式人PAI-1(PAI-1-stab)的转基因小鼠表现出复杂的表型异常,包括脱发和肝脾肿大。表达无活性PAI-1的活性位点突变转基因小鼠表现出完全的表型挽救,而表达对玻连蛋白亲和力降低的PAI-1的转基因小鼠表现出PAI-1-stab转基因小鼠中存在的所有表型异常。

结论

PAI-1对PAs和/或其他丝氨酸蛋白酶的蛋白酶抑制活性对于促进复杂的表型异常是必要且充分的,并介导了PAI-1在体内的许多生理作用。

相似文献

1
Reactive site-dependent phenotypic alterations in plasminogen activator inhibitor-1 transgenic mice.纤溶酶原激活物抑制剂-1转基因小鼠中反应位点依赖性的表型改变
J Thromb Haemost. 2007 Jul;5(7):1500-8. doi: 10.1111/j.1538-7836.2007.02587.x. Epub 2007 Apr 16.
2
Transgenic over-expression of plasminogen activator inhibitor-1 results in age-dependent and gender-specific increases in bone strength and mineralization.纤溶酶原激活物抑制剂-1的转基因过表达导致骨强度和矿化随年龄增长和性别特异性增加。
Bone. 2007 Dec;41(6):995-1004. doi: 10.1016/j.bone.2007.08.020. Epub 2007 Aug 17.
3
Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1.表达稳定形式人纤溶酶原激活物抑制剂-1的转基因小鼠中年龄依赖性自发性冠状动脉血栓形成
Circulation. 2002 Jul 23;106(4):491-6. doi: 10.1161/01.cir.0000023186.60090.fb.
4
A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis.由半胱氨酸突变产生的新型纤溶酶原激活物抑制剂延长了其半衰期:与癌症和血管生成的相关性。
Mol Cancer Ther. 2003 Jan;2(1):19-28.
5
Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries.噬菌体展示的高突变纤溶酶原激活物抑制剂1(PAI-1)文库证明,潜伏期转变和蛋白酶抑制过程中PAI-1的不同结构要求。
J Mol Biol. 2001 Jan 26;305(4):773-83. doi: 10.1006/jmbi.2000.4356.
6
Determination of the vitronectin binding site on plasminogen activator inhibitor 1 (PAI-1).纤溶酶原激活物抑制剂1(PAI-1)上玻连蛋白结合位点的测定。
FEBS Lett. 1994 Oct 3;352(3):342-6. doi: 10.1016/0014-5793(94)00990-2.
7
Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.尿激酶型纤溶酶原激活物-纤溶酶原激活物抑制剂-1复合物与内吞作用受体α2-巨球蛋白受体/低密度脂蛋白受体相关蛋白及极低密度脂蛋白受体的结合涉及抑制剂中的碱性残基。
Biochem J. 1998 Jan 1;329 ( Pt 1)(Pt 1):55-63. doi: 10.1042/bj3290055.
8
Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis.通过定点诱变鉴定1型纤溶酶原激活物抑制剂低分子量抑制剂的结合位点。
Biochemistry. 1998 Feb 3;37(5):1227-34. doi: 10.1021/bi971554q.
9
Introduction of an RRHR motif into chicken urokinase-type plasminogen activator (ch-uPA) confers sensitivity to plasminogen activator inhibitor (PAI)-1 and PAI-2 and allows ch-uPA-mediated extracellular matrix degradation to be controlled by PAI-1.将RRHR基序引入鸡尿激酶型纤溶酶原激活剂(ch-uPA)可使其对纤溶酶原激活剂抑制剂(PAI)-1和PAI-2敏感,并使ch-uPA介导的细胞外基质降解受PAI-1控制。
Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):2933-8. doi: 10.1073/pnas.94.7.2933.
10
Localization of vitronectin binding domain in plasminogen activator inhibitor-1.纤溶酶原激活物抑制剂-1中玻连蛋白结合域的定位
J Biol Chem. 1994 May 27;269(21):15223-8.

引用本文的文献

1
PAI-1: A Major Player in the Vascular Dysfunction in Obstructive Sleep Apnea?PAI-1:阻塞性睡眠呼吸暂停中血管功能障碍的主要参与者?
Int J Mol Sci. 2022 May 15;23(10):5516. doi: 10.3390/ijms23105516.
2
Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition.心血管疾病中靶向纤溶酶原激活物抑制剂-1:纤溶酶原激活物抑制剂-1功能及抑制作用的结构见解
Front Cardiovasc Med. 2020 Dec 22;7:622473. doi: 10.3389/fcvm.2020.622473. eCollection 2020.
3
PAI-1 is a critical regulator of FGF23 homeostasis.PAI-1 是 FGF23 动态平衡的关键调节因子。
Sci Adv. 2017 Sep 13;3(9):e1603259. doi: 10.1126/sciadv.1603259. eCollection 2017 Sep.
4
TGF-β-induced intracellular PAI-1 is responsible for retaining hematopoietic stem cells in the niche.转化生长因子-β诱导的细胞内纤溶酶原激活物抑制因子-1负责将造血干细胞保留在生态位中。
Blood. 2017 Nov 23;130(21):2283-2294. doi: 10.1182/blood-2017-02-767384. Epub 2017 Aug 18.
5
Plasminogen Activator Inhibitor-1 Is a Marker and a Mediator of Senescence.纤溶酶原激活物抑制剂-1是衰老的一个标志物和介质。
Arterioscler Thromb Vasc Biol. 2017 Aug;37(8):1446-1452. doi: 10.1161/ATVBAHA.117.309451. Epub 2017 Jun 1.
6
Role of plasminogen activator inhibitor-1 in senescence and aging.纤溶酶原激活物抑制剂-1在衰老和老化中的作用。
Semin Thromb Hemost. 2014 Sep;40(6):645-51. doi: 10.1055/s-0034-1387883. Epub 2014 Aug 31.
7
Functionally stable plasminogen activator inhibitor-1 in a family with cardiovascular disease and vitiligo.患有心血管疾病和白癜风的家族中功能稳定的纤溶酶原激活物抑制剂-1
J Thromb Thrombolysis. 2014 Jul;38(1):50-6. doi: 10.1007/s11239-013-1021-x.
8
Plasminogen activator inhibitor-1 antagonist TM5441 attenuates Nω-nitro-L-arginine methyl ester-induced hypertension and vascular senescence.纤溶酶原激活物抑制剂-1 拮抗剂 TM5441 可减轻 Nω-硝基-L-精氨酸甲酯诱导的高血压和血管衰老。
Circulation. 2013 Nov 19;128(21):2318-24. doi: 10.1161/CIRCULATIONAHA.113.003192. Epub 2013 Oct 3.
9
Plasminogen activator inhibitor-1: a novel therapeutic target for hypertension?纤溶酶原激活物抑制剂-1:高血压的新型治疗靶点?
Circulation. 2013 Nov 19;128(21):2286-8. doi: 10.1161/CIRCULATIONAHA.113.006321. Epub 2013 Oct 3.
10
The vitronectin-binding domain of plasminogen activator inhibitor-1 plays an important functional role in lipopolysaccharide-induced lethality in mice.纤溶酶原激活物抑制剂-1的玻连蛋白结合结构域在脂多糖诱导的小鼠致死性中发挥重要功能作用。
J Thromb Haemost. 2012 Dec;10(12):2618-21. doi: 10.1111/jth.12032.